DE2215864A1 - Derivate von Dihydro-l,2,4-benzothiadiazin-l,l-dioxid und Verfahren zu ihrer Herstellung - Google Patents
Derivate von Dihydro-l,2,4-benzothiadiazin-l,l-dioxid und Verfahren zu ihrer HerstellungInfo
- Publication number
- DE2215864A1 DE2215864A1 DE19722215864 DE2215864A DE2215864A1 DE 2215864 A1 DE2215864 A1 DE 2215864A1 DE 19722215864 DE19722215864 DE 19722215864 DE 2215864 A DE2215864 A DE 2215864A DE 2215864 A1 DE2215864 A1 DE 2215864A1
- Authority
- DE
- Germany
- Prior art keywords
- radical
- compounds
- carbon atoms
- dioxide
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 3
- -1 alkyl radical Chemical class 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 16
- 150000002148 esters Chemical class 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 5
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 238000007127 saponification reaction Methods 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 4
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 239000002253 acid Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 238000006798 ring closing metathesis reaction Methods 0.000 description 3
- 150000004684 trihydrates Chemical class 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002497 edematous effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000000894 saliuretic effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical class C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- JTAOUTUYXLKYSK-UHFFFAOYSA-N 4-anilino-3-(benzylamino)-5-sulfamoylbenzoic acid Chemical compound C=1C=CC=CC=1NC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1NCC1=CC=CC=C1 JTAOUTUYXLKYSK-UHFFFAOYSA-N 0.000 description 1
- VNAIJMNTNXYYTA-UHFFFAOYSA-N 4-anilino-3-(butylamino)-5-sulfamoylbenzoic acid Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1NC1=CC=CC=C1 VNAIJMNTNXYYTA-UHFFFAOYSA-N 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 150000007658 benzothiadiazines Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- LTYRAPJYLUPLCI-UHFFFAOYSA-N glycolonitrile Chemical compound OCC#N LTYRAPJYLUPLCI-UHFFFAOYSA-N 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000004987 o-phenylenediamines Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB831771 | 1971-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2215864A1 true DE2215864A1 (de) | 1972-10-12 |
Family
ID=9850217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19722215864 Pending DE2215864A1 (de) | 1971-03-31 | 1972-03-30 | Derivate von Dihydro-l,2,4-benzothiadiazin-l,l-dioxid und Verfahren zu ihrer Herstellung |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US3845045A (enExample) |
| DE (1) | DE2215864A1 (enExample) |
| FR (1) | FR2132202B1 (enExample) |
| GB (1) | GB1330033A (enExample) |
| IE (1) | IE36138B1 (enExample) |
| NL (1) | NL7203343A (enExample) |
-
1971
- 1971-03-31 GB GB831771A patent/GB1330033A/en not_active Expired
-
1972
- 1972-03-06 IE IE273/72A patent/IE36138B1/xx unknown
- 1972-03-08 US US00232963A patent/US3845045A/en not_active Expired - Lifetime
- 1972-03-14 NL NL7203343A patent/NL7203343A/xx unknown
- 1972-03-29 FR FR7211103A patent/FR2132202B1/fr not_active Expired
- 1972-03-30 DE DE19722215864 patent/DE2215864A1/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB1330033A (en) | 1973-09-12 |
| IE36138B1 (en) | 1976-09-01 |
| US3845045A (en) | 1974-10-29 |
| NL7203343A (enExample) | 1972-10-03 |
| FR2132202A1 (enExample) | 1972-11-17 |
| IE36138L (en) | 1972-09-30 |
| FR2132202B1 (enExample) | 1975-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE903578C (de) | Verfahren zur Herstellung von neuen, in 4-Stellung substituierten 3, 5-Dioxo-pyrazolidinen | |
| EP0621037B1 (de) | Pyrido-pyrimidindione, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
| DE1545772B1 (de) | 7-(3'-Picolylamino-alkyl)-theophylline und deren nikotinsaure Salze | |
| DE1965711C3 (de) | l^-Dihydro-133-triazin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE2215864A1 (de) | Derivate von Dihydro-l,2,4-benzothiadiazin-l,l-dioxid und Verfahren zu ihrer Herstellung | |
| DE2121694C3 (enExample) | ||
| DE1795344A1 (de) | 3-Amino-isothiazole | |
| DE1179218B (de) | Verfahren zur Herstellung von Riboflavin-2', 3', 4', 5'-tetrabuttersaeureester | |
| DE2414345C3 (de) | (Z)-(3-Methyl-4-oxo-5-piperidinothiazolidin-2-yIiden)-esssigsäure und Verfahren zur Herstellung von Thiazolidinessigsäure-Derivaten | |
| DE1620747C3 (de) | Carbothiamin sowie dessen nichttoxische organische oder anorganische Säureadditionssalze sowie Verfahren zur Herstellung dieser Verbindungen | |
| DE2543821C2 (de) | Bestimmte Salze und Ester von 1-Aminomethyl-1-cycloalkanessigsäuren und diese Verbindungen enthaltende Arzneimittel | |
| DE1229543B (de) | Verfahren zur Herstellung von 1, 3-Dithia-2-arsacyclopentan-4, 5-dicarbonsaeuren | |
| DE1253717C2 (de) | Verfahren zur herstellung von o,s-dialkoxycarbonyl-vitamin b tief 1derivaten | |
| AT323154B (de) | Verfahren zur herstellung von neuen 5-methoxy-2-methylindol-3-essigsäurederivaten sowie von deren salzen | |
| DE2241076A1 (de) | Tetracyclinkomplex, verfahren zu dessen herstellung und diesen komplex enthaltende pharmazeutische zusammensetzungen | |
| DE1793483C3 (de) | 2,6-Dichlorphenylacetyl-bzw. 2,6-Dimethylphenylacetyl guanidin, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel | |
| DE2065966B2 (de) | N-Fluorenyl-sulfonyl-aminocarbonsäuren sowie diese enthaltende Mittel | |
| DE1962493C3 (de) | Thiazolylbenzoesäurederivate und Verfahren zu ihrer Herstellung | |
| DE1545753C (de) | Tnsubstituierte s Triazine und Ver fahren zu ihrer Herstellung | |
| DE3313599A1 (de) | Neue benzimidazolderivate | |
| DE901173C (de) | Verfahren zur Herstellung von Salzen von Diamidinbasen | |
| DE2462837C2 (de) | (Z)-(3-Äthyl-4-oxo-5-piperidinothiazolidin-2-yliden)-essigsäure | |
| DE2061994A1 (de) | Substituierte Anthramlsauren | |
| DE3409403A1 (de) | Lipoxygenasehemmendes arzneimittel | |
| DE2218248C3 (de) | Picolinsäure-dithiocarbamate |